Qube Research & Technologies (QRT)
QNCX icon

Qube Research & Technologies (QRT)’s Quince Therapeutics QNCX Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio QNCX Stock Details QNCX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-392
Closed -$263K – 4005
2025
Q4 		$263K Buy
+392
New +$197K ﹤0.01% 2993
2022
Q4 		– Sell
-68
Closed -$18K – 2893
2022
Q3 		$18K Sell
68
-53
-44% -$20.2K ﹤0.01% 2311
2022
Q2 		$54K Buy
+121
New +$85.5K ﹤0.01% 2105

Other funds holding QNCX

WP
Woodline Partners San Francisco, California $26.4B AUM 44.85% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

Qube Research & Technologies (QRT)'s QNCX Position: Q1 2026 in Review

Qube Research & Technologies (QRT) sold out of Quince Therapeutics (QNCX) in Q1 2026, closing a stake of 392 shares — an estimated $263K sold.

Qube Research & Technologies (QRT) first reported a position in QNCX in Q2 2022 and held it in 3 quarters. The position peaked at $263K in Q4 2025. 43 funds tracked by Wall St. Rank hold QNCX as of Q1 2026.

  • Qube Research & Technologies (QRT) reported no remaining Quince Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 392 Quince Therapeutics shares in Q1 2026, an estimated $263K.
  • Qube Research & Technologies (QRT) first reported a position in Quince Therapeutics in Q2 2022 and held it in 3 quarters.
  • Qube Research & Technologies (QRT)'s Quince Therapeutics position peaked at $263K in Q4 2025.
  • 43 funds tracked by Wall St. Rank held Quince Therapeutics as of Q1 2026.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2026, filed 15 May 2026.